

LYMPHOID NEOPLASIA

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTK^{Cys481} ibrutinib resistance

Guang Yang,^{1,2} Jinhua Wang,³ Li Tan,³ Mani Munshi,¹ Xia Liu,¹ Amanda Kofides,¹ Jiaji G. Chen,¹ Nicholas Tsakmaklis,¹ Maria G. Demos,¹ Maria Luisa Guerrero,¹ Lian Xu,¹ Zachary R. Hunter,^{1,2} Jinwei Che,³ Christopher J. Patterson,¹ Kirsten Meid,¹ Jorge J. Castillo,^{1,2} Nikhil C. Munshi,^{2,4} Kenneth C. Anderson,^{2,4} Michael Cameron,⁵ Sara J. Buhrlage,³ Nathanael S. Gray,³ and Steven P. Treon^{1,2}

¹Bing Center for Waldenström's Macroglobulinemia; ²Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; ³Department of Cancer Biology, Dana-Farber Cancer Institute, and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA; ⁴Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA; and ⁵Department of Molecular Medicine, Scripps Research, La Jolla, CA

KEY POINTS

- KIN-8194 is a highly potent dual HCK and BTK inhibitor with superior antitumor activity over ibrutinib in MYD88-mutated B-cell lymphomas.
- KIN-8194 overcomes ibrutinib resistance with a survival benefit in TMD-8 ABC DLBCL xenografted mice and synergizes with venetoclax.

Activating mutations in MYD88 promote malignant cell growth and survival through hematopoietic cell kinase (HCK)-mediated activation of Bruton tyrosine kinase (BTK). Ibrutinib binds to BTK^{Cys481} and is active in B-cell malignancies driven by mutated MYD88. Mutations in BTK^{Cys481}, particularly BTK^{Cys481Ser}, are common in patients with acquired ibrutinib resistance. We therefore performed an extensive medicinal chemistry campaign and identified KIN-8194 as a novel dual inhibitor of HCK and BTK. KIN-8194 showed potent and selective in vitro killing of MYD88-mutated lymphoma cells, including ibrutinib-resistant BTK^{Cys481Ser}-expressing cells. KIN-8194 demonstrated excellent bioavailability and pharmacokinetic parameters, with good tolerance in rodent models at pharmacologically achievable and active doses. Pharmacodynamic studies showed sustained inhibition of HCK and BTK for 24 hours after single oral administration of KIN-8194 in an MYD88-mutated TMD-8 activated B-cell diffuse large B-cell lymphoma (ABC DLBCL) and BCWM.1 Waldenström macroglobulinemia (WM) xenografted mice with wild-type BTK (BTK^{WT}) or BTK^{Cys481Ser}-expressing tumors. KIN-8194 showed superior survival benefit over ibrutinib in both BTK^{WT}- and BTK^{Cys481Ser}-expressing TMD-8 DLBCL xenografted mice, including sustained complete responses of >12 weeks off treatment in mice with BTK^{WT}-expressing TMD-8 tumors. The BCL-2 inhibitor venetoclax enhanced the antitumor activity of KIN-8194 in BTK^{WT}- and BTK^{Cys481Ser}-expressing MYD88-mutated lymphoma cells and markedly reduced tumor growth and prolonged survival in mice with BTK^{Cys481Ser}-expressing TMD-8 tumors treated with both drugs. The findings highlight the feasibility of targeting HCK, a key driver of mutated MYD88 pro-survival signaling, and provide a framework for the advancement of KIN-8194 for human studies in B-cell malignancies driven by HCK and BTK.

Introduction

Activating mutations in MYD88 are prevalent in Waldenström macroglobulinemia (WM; 95% to 97%), primary central nervous system lymphoma (PCNSL; 60% to 80%), activated B-cell diffuse large B-cell lymphoma (ABC DLBCL; 30% to 40%), chronic lymphocytic leukemia (CLL; 5% to 10%), and marginal zone lymphoma (MZL; 5% to 10%).¹⁻⁶ Mutated MYD88 triggers auto-assembly of a myddosome complex that includes Bruton tyrosine kinase (BTK), which triggers downstream NF-κB pro-survival signaling.⁷ Moreover, mutated MYD88 transcriptionally upregulates the SRC family member hematopoietic cell kinase (HCK) through regulation that involves PAX5 and activates HCK through interleukin-6 (IL-6).^{8,9} HCK in turn activates BTK permitting it to join the myddosome signaling complex and trigger other

pro-survival pathways, including PI3K/AKT, MAPK/ERK1/2, and SYK/STAT3/AKT.^{7,9,10} Ibrutinib blocks BTK activity by covalently binding to BTK^{Cys481} and is active in MYD88-mutated WM, PCNSL, ABC DLBCL, CLL, and MZL.¹¹⁻¹⁴ Other covalent and non-covalent inhibitors of BTK are also in clinical use or are under development for MYD88-mutated B-cell malignancies.

Acquired resistance to ibrutinib as a result of BTK^{Cys481} mutations is common in WM, CLL, and MZL.¹⁵⁻¹⁸ Our previous studies showed that mutations in BTK^{Cys481} restore downstream pro-survival signaling that includes NF-κB and ERK1/2.¹⁹ The latter facilitates release of inflammatory mediators, including IL-6 and IL-10, that trigger resistance in neighboring wild-type BTK (BTK^{WT}) cells. Because BTK is activated by HCK, we sought to develop HCK inhibitors to overcome ibrutinib resistance in mutated

BTK^{Cys481}-expressing WM and ABC DLBCL lymphomas driven by mutated MYD88. In a previous study, we showed that a toolbox HCK inhibitor, A419259, overcame in vitro ibrutinib resistance mediated by mutated BTK^{Cys481}.⁸ We therefore screened >220 clinical and preclinical kinase inhibitors and performed lead optimization with iterative rounds of synthesis of >400 analogs. These efforts resulted in the identification of 2 lead compounds, KIN-8193 and KIN-8194. KIN-8193, a potent HCK inhibitor derived from a preclinical toolbox compound, TLR-2-59, blocked BTK activity and overcame ibrutinib resistance related to mutated BTK^{Cys481} but demonstrated a tight therapeutic index.²⁰ KIN-8194, a dual BTK/HCK inhibitor described herein, has a chemical structure similar to but distinct from that of A419259 (RK-20449).^{21,22} In this report, we present our findings characterizing the in vitro and in vivo activity of KIN-8194 in MYD88-mutated lymphomas, including in ibrutinib-resistant tumor models.

Materials and methods

Cell lines and reagents

MYD88-mutated (MYD88^{L265P}) WM (BCWM.1 and MWCL-1), ABC DLBCL (TMD-8, HBL1), and wild-type (MYD88^{WT}) germinal center B-cell like (GCB) DLBCL (OCI-Ly7, OCI-Ly19), Burkitt's lymphoma (Ramos), and myeloma (RPMI-8226) cells were used. Their identities were confirmed by short tandem repeat profiles with GenePrint 10 System (Promega, Fitchburg, WI). Ibrutinib and venetoclax were obtained from MedChem Express (Monmouth Junction, NJ).

Patient samples

Mononuclear cells from bone marrow (BM) aspirates were isolated using Ficoll-Paque PLUS Media (GE Healthcare) and 2×10^6 BM mononuclear cells treated overnight (for apoptosis) or for 1 to 2 hours (for Phosflow) with ibrutinib or KIN-8194. Apoptosis or Phosflow analyses were performed on CD19⁺ (for apoptosis) or CD20⁺ (for Phosflow) lymphoplasmacytic cells (LPCs). MYD88 genotyping was performed as before.^{1,2} Peripheral blood mononuclear cells from healthy donors were used as controls. Sample use was approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board after patients provided written consent.

Kinase profiling and enzymatic assays

KINOMEScan assays were performed to quantitatively measure interactions between KIN-8194 and 468 kinases in vitro at Eurofins DiscoverX Corporation (San Diego, CA).²³ Scores for primary screens were reported as a percent of dimethyl sulfoxide (DMSO) control. Selectivity score was defined as the ratio of kinases inhibited to a specified percentage vs total number of kinases, excluding mutant variants. Enzymatic activities against HCK and BTK were tested in Z-Lyte assays with adenosine triphosphate (ATP) concentrations of at Km [app] adenosine triphosphate (ATP) concentrations (Thermo Fisher Scientific, Waltham, MA).

Live-cell target engagement studies

Live-cell kinase target engagement profiling with KiNativ was performed by ActivX Biosciences (La Jolla, CA).²⁴ Briefly, live (TMD-8) cells were pretreated with DMSO or 1.0 μ M KIN-8194 for 90 minutes, then washed twice with ice-cold phosphate-buffered saline. Cell pellets were snap-frozen in liquid nitrogen and sent for KiNativ profiling. HCK- and BTK-specific targeting was also assessed using Pierce Kinase Enrichment Kit with ActivX

Desthiobiotin-ATP Probe (Thermo Fisher Scientific) after treatment of BCWM.1 and TMD-8 cells with serially diluted KIN-8194 or ibrutinib for 90 minutes with ATP-binding to HCK or BTK resolved by western blotting.

Computational docking models

Molecular models were constructed by ligand alignment with the corresponding co-crystal structure small molecules of BTK (Protein Data Bank identification number [pdb: 5P9J]) and HCK (pdb: 5ZJ6) and energy minimized by refining the protein-ligand complex protocol with default parameters using Schrodinger Glide Docking (version 2020-04). Water molecules observed in the pdb structures around the ligand were conserved and optimized. Binding energies were estimated with docking scores by using place scoring method (Glide version 2020-04).

In vitro cellular efficacy studies

In vitro cellular efficacies were assessed by using a CellTiter-Glo Luminescent Cell Viability Assay (Promega).^{7,10,19} Dose-response curves were calculated with GraphPad Prism software. Drug interactions were assessed by using CalcuSyn 2.0 software (Biosoft, Cambridge, United Kingdom). Apoptosis was assessed by using an Apoptosis Detection Kit (BD Pharmingen, San Diego, CA). Cells (1×10^6 cells per well) were treated with inhibitors overnight in 24-well plates. A minimum of 10 000 events was acquired by using a BD FACSCanto II flow cytometer, and the results were analyzed with FlowJo software. WM patient LPCs (2×10^6 cells per well) were treated with inhibitors, and CD19-APC-Cy7 antibody (BD Biosciences, San Jose, CA) was used with an annexin V antibody to evaluate apoptosis.

Signaling studies

Cells were treated for 1 to 2 hours before Phosflow, and immunoblotting studies were performed using antibodies to phycoerythrin-conjugated pBTK (Y223), APC-Cy7-conjugated CD20 (BD Biosciences); pBTK(Y223), pHCK(Y410), pIRAK1 (T209), DyLight 650-conjugated goat F(ab')₂ anti-rabbit immunoglobulin G (IgG) secondary antibody (Abcam, Cambridge, MA); pSYK(Y525/526) (R&D Systems); and Alexa Fluor 647-conjugated pSYK(Y525/526), SYK, pAKT(S473), AKT, pERK1/2(T202/Y204), ERK1/2, BTK, HCK (Cell Signaling Technologies, MA).^{7,8} Glyceraldehyde-3-phosphate dehydrogenase antibody (Santa Cruz Biotechnology, Dallas, TX) was used as loading control for immunoblotting.

Generation of HCK^{Thr333Met}- or BTK^{Cys481Ser}-expressing cell lines

Cell lines expressing HCK^{WT} or a mutated gatekeeper residue (HCK^{Thr333Met}) along with BTK^{WT} or BTK^{Cys481Ser} were generated by lentiviral transduction in a pLVX-EF1 α -IRES-Puro vector (Clontech Laboratories, Palo Alto, CA).^{8,19} After lentiviral transduction, stable cell lines were selected with 0.5 to 1.0 μ g/mL puromycin. Expression of transduced coding sequences was confirmed by Sanger sequencing after gene-specific reverse transcription polymerase chain reaction, and protein expression was confirmed by immunoblotting. For xenografted murine models, TMD-8 ABC DLBCL cells were co-transduced to express luciferase and green fluorescent protein (GFP) using a pLenti-II-CMV-Luc-IRES-GFP lentiviral vector (Applied Biological Materials, Vancouver, BC, Canada).

Pharmacokinetic studies

Pharmacokinetic (PK) studies were performed at Scripps Florida under an Institutional Animal Care and Use Committee (IACUC)-approved protocol. C57BL/6 mice were administered A419259 or KIN-8194 in normal saline by tail vein intravenous injection at 2 mg/kg or orally at 10 or 25 mg/kg. Plasma concentrations were determined by liquid chromatography-tandem mass spectrometry after mass transition 49600→340 AMU. PK parameters were calculated by using Phoenix WinNonlin.

Pharmacodynamic and in vivo efficacy studies

BTK^{WT}- or BTK^{Cys481Ser}-expressing TMD-8 ABC DLBCL cells were xenografted into mice for pharmacodynamic (PD) and in vivo efficacy studies. Female NOD-SCID mice (Strain Code 394) age 6 to 8 weeks weighing 16 to 20 g were obtained from Charles River Laboratories (Shrewsbury, MA). Animal studies were performed under IACUC-approved protocols at the Experimental Therapeutics Core at Dana-Farber Cancer Institute. KIN-8194 tolerability was determined in a 14-day daily dosing study which showed that doses up to 75 mg/kg per day were tolerable. Then, 1×10^7 GFP⁺ BTK^{WT}- or BTK^{Cys481Ser}-expressing TMD-8 cells were subcutaneously inoculated in a Matrigel suspension (Corning Life Sciences, Tewksbury, MA). In PD studies, when tumor size approximated 300 mm³, mice were treated with KIN-8194 at the indicated dose by oral gavage. At 6 or 24 hours after administration of KIN-8194, mice were euthanized in a CO₂ chamber, and tumors that were harvested mechanically were dissociated to form single-cell suspensions. Phosflow studies were performed for pHCK^{Y410} and pBTK^{Y223} in GFP⁺ tumor cells. PD studies showing changes in HCK and BTK activity after oral administration of KIN-8194 were also performed in NOD-SCID mice xenografted with BTK^{WT} BCWM.1 WM cells by intravenous injection. Phosflow for pHCK^{Y410} and pBTK^{Y223} in GFP⁺ BCWM.1 WM cells was performed on mononuclear cells obtained from mouse femurs at 6 and 24 hours after oral administration of vehicle control or KIN-8194 at 25 or 50 mg/kg. For in vivo efficacy studies, mice were randomly assigned to each cohort when tumors reached ~200 mm³ and were treated once per day with vehicle, ibrutinib, A419259, KIN-8194, or any of those combined with venetoclax at the indicated dose by oral gavage ($n = 8$ mice per cohort). Tumor volumes were measured twice per week and calculated as tumor volume ($[\text{length} \times \text{width}^2] \times 0.5$).

Statistical analysis

Statistical significance of differences was analyzed using one-way analysis of variance with Tukey's multiple comparisons test by Prism software. Differences were considered significant at $P < .05$. Error bars where shown denote standard deviation. The Kaplan-Meier method was used to estimate survival curves, and the curves were compared using the log-rank test.

Results

KIN-8194 selectively targets HCK and BTK in MYD88-mutated WM and ABC DLBCL cells

The chemical structure of KIN-8194 is depicted in Figure 1A. KIN-8194 has a chemical structure similar to but distinct from that of A419259 (RK-20449), a toolbox compound we previously characterized in MYD88 lymphomas, including ibrutinib-resistant BTK^{Cys481} mutant-expressing cells (supplemental Figure 1).⁸ KIN-8194 demonstrated greater selectivity compared with A419259

with no KIT, RET, PDGFRA, EPHB6, or CDPK1 inhibition (at 90% kinase inhibition), an important consideration because several of these targets have well-known toxicity concerns (supplemental Table 1). Biochemical kinase assays demonstrated that KIN-8194 strongly inhibited HCK (50% inhibitory dose [IC₅₀] <0.495 nM) and BTK (IC₅₀, 0.915 nM). By comparison in a fixed time-point assay, ibrutinib exhibited similar BTK inhibition (IC₅₀, 0.614 nM), and 100-fold less potent HCK inhibition (IC₅₀, 49 nM). To assess the kinase target selectivity of KIN-8194, we performed a KINO-MEscan assay against a panel of 468 kinases. KIN-8194 at 0.1 and 1.0 μM showed S10 selectivity scores of 0.07 and 0.12, with targets mainly limited to Src (ie, HCK, BLK, LYN, and FRK) and Tec (ie, BTK) family kinases (Figure 1B; supplemental Table 2). To further evaluate the kinome selectivity of KIN-8194 and verify its target engagement in living cells, we performed KiNativ profiling in TMD-8 ABC DLBCL cells at 1.0 μM which confirmed that KIN-8194 strongly engaged both HCK and BTK (Figure 1C; supplemental Table 3). An ATP-competitive assay was also performed using Pierce Kinase Enrichment Kit with an ActivX desthiobiotin-ATP probe after live cell were pretreated with KIN-8194 in MYD88-mutated BCWM.1 WM cells and TMD-8 ABC DLBCL cells. The enriched kinases were resolved by western blots and showed robust engagement of HCK by KIN-8194 and a level of BTK binding for KIN-8194 similar to that of ibrutinib (Figure 1D).

KIN-8194 binds to gatekeeper residue Thr³³³ of HCK but not to Cys⁴⁸¹ of BTK

To clarify the mode of recognition of the ATP pocket by KIN-8194, we performed a docking study of KIN-8194 into the co-crystal structure of HCK with A419259 (pdb:5zj6) and BTK with ibrutinib (pdb:5p9i). The docking study predicted that KIN-8194 would recognize the ATP-binding pocket of HCK with an estimated binding energy (ΔG) of 13.4 kcal/mol. The 4-amino group of KIN-8194 is predicted to form a hydrogen bond with the carbonyl groups of the gatekeeper residue Thr³³³ and also with Glu³³⁴ of HCK; its 3-nitrogen atom as an H-bond acceptor interacted with the backbone amino group of Met³³⁶ of HCK (supplemental Figure 2A). KIN-8194 also exhibited similar interactions involving Thr⁴⁷⁴, Glu⁴⁷⁵, and Met⁴⁷⁷, but not Cys⁴⁸¹ of BTK with an estimated binding energy of −13.0 kcal/mol (supplemental Figure 2B).

KIN-8194 shows robust inhibition of both HCK and BTK activity in MYD88-mutated cells

We next assessed the ability of KIN-8194 and ibrutinib to inhibit HCK and BTK in MYD88-mutated cells by evaluating changes in phosphorylation of HCK^{Tyr410} and BTK^{Tyr223}. Ibrutinib modestly inhibited HCK phosphorylation, whereas KIN-8194 showed robust inhibition of HCK^{Tyr410} phosphorylation (Figure 2A; supplemental Figure 3). A similar level of inhibition for BTK^{Tyr223} phosphorylation was also observed for ibrutinib and KIN-8194 (Figure 2B). KIN-8194 more potently suppressed both HCK and BTK activity compared with ibrutinib in primary patient BM LPCs in the presence of cells that support the microenvironment (Figure 2C).

KIN-8194 blocks HCK and BTK and inhibits the growth and survival of MYD88-mutated WM and ABC DLBCL cells

We next evaluated the antiproliferative effects of KIN-8194 in MYD88-mutated and WT cell lines. KIN-8194 showed marked and targeted antitumor activity against MYD88-mutated cell lines with cellular efficacies more potent than those of ibrutinib




Figure 1. KIN-8194 selectively targets HCK and BTK in vitro in MYD88-mutated WM and ABC DLBCL cells. (A) Chemical structure of KIN-8194. (B) KINOMEScan kinase selectivity profile for KIN-8194. KIN-8194 was profiled at a concentration of 1.0 μ M against a diverse panel of 464 kinases by using DiscoverX. Kinases that exhibited a score of 10% or below are marked in red circles. (C) KiNativ cellular target engagement profile for KIN-8194. Kinases engaged >50% with 1.0 μ M KIN-8194 treatment in TMD-8 cells are labeled. Kinases demonstrating >90% inhibition in KiNativ profiling (as shown in supplemental Table 2) were subjected to enzymatic IC₅₀ determination as shown here. (D) Activated kinases enriched by pulldown assay using Desthiobiotin-ATP Probe after BCWM.1 and TMD-8 live cells pretreated with KIN-8194 or ibrutinib at indicated concentrations for 90 minutes and the ATP-binding HCK and BTK were resolved by western blotting. IB, ibrutinib.

(Figure 2D; supplemental Table 4). Conversely, MYD88-mutated OCI-Ly3 cells bearing the CARD11 mutation showed no antitumor effects from either ibrutinib or KIN-8194 (supplemental Figure 4). We also assessed the antitumor activity of KIN-8194 by using primary MYD88-mutated BM LPCs from 6 WM patients and compared its effect in autologous T cells from these patients, and in peripheral blood B and T cells from 6 healthy donors. KIN-8194 produced more robust apoptosis compared with ibrutinib against primary WM LPCs. No notable apoptosis was observed for KIN-8194 against T cells from patients who had received an

autologous stem cell transplantation or B and T cells from healthy donors (Figure 2E).

HCK and BTK are key targets of KIN-8194 in MYD88-mutated lymphoma cells

To confirm the key functional targets of KIN-8194 in MYD88-mutated B-cell lymphomas, we generated HCK gatekeeper mutant HCK^{T333M} transduced cell models and performed rescue experiments in MYD88-mutated BCWM.1 and MWCL-1 cells. Expression of HCK^{T333M} produced an approximately log2




Figure 2. KIN-8194 blocks HCK and BTK and inhibits the growth and survival of MYD88-mutated WM and ABC DLBCL cells. (A) Representative experiments showing changes in phosphorylated HCK (pHCK^{Tyr410}) or (B) phosphorylated BTK (pBTK^{Tyr223}) levels after 1.0-hour treatment with KIN-8194 or ibrutinib at the indicated concentrations in MYD88-mutated WM (BCWM.1, MWCL-1) and ABC DLBCL (TMD-8, HBL-1) cell lines ($n = 3$ mice per treatment group). (C) Phosflow results for pHCK^{Tyr410} and pBTK^{Tyr223} in BM LPCs for MYD88-mutated WM patients after treatment with KIN-8194 or ibrutinib at indicated concentrations for 2.0 hours in the presence of whole BM mononuclear cells ($n = 4$). (D) Dose-response curves for MYD88^{WT} and MYD88^{L265P} cell lines after treatment with KIN-8194 or ibrutinib for 72 hours at indicated concentrations. (E) Apoptotic studies using annexin V/propidium iodide (PI) staining for primary BM LPCs and T cells from MYD88-mutated patients ($n = 6$) and peripheral blood B cells and T cells from healthy donors (HDs) ($n = 6$) after treatment with ibrutinib or KIN-8194 at indicated concentrations for 16 hours. * $P < .05$; ** $P < .01$; **** $P < .0001$. DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; norm, normalized; RLU, relative light unit.




Figure 3. HCK and BTK are key targets of KIN-8194 activity in MYD88-mutated WM cells. (A) Dose-response curves for vector only, HCK^{WT}, or HCK^{T333M} transduced BCWM.1 and MWCL-1 WM cells after treatment with KIN-8194 for 72 hours. (B) Relative pHCK^{Tyr410} levels by Phosflow analysis treatment of KIN-8194 at indicated concentrations for 1.0 hours in vector only, HCK^{WT}, or HCK^{T333M} transduced MYD88-mutated BCWM.1 and MWCL-1 WM cells. (C) pBTK^{T223}, pSYK^{Y525/526}, pAKT^{S473}, pERK1/2^{T202/Y204} expression by western blot analysis in HCK^{WT} or HCK^{T333M} transduced BCWM.1 and MWCL-1 WM cells after treatment with KIN-8194 at indicated concentrations for 1.0 hours. The expression levels of total BTK, SYK, AKT, and ERK1/2 in these cells and protein loading control GAPDH are also shown. Experiments were performed at least twice, with representative blots shown. Ab, antibody.

fold-change increase in resistance to KIN-8194 compared with vector or HCK^{WT}-transduced BCWM.1 and MWCL-1 cells (Figure 3A; supplemental Table 4). In addition to these findings, we observed that expression of HCK^{T333M}, but not HCK^{WT}, led to persistent activation of HCK in the presence of KIN-8194 (Figure 3B).

Because HCK triggers multiple pro-survival pathways in MYD88-mutated lymphoma cells, we next treated HCK^{WT}- or HCK^{T333M}-expressing BCWM.1 and MWCL-1 cells with KIN-8194 and assessed the activation state of BTK, AKT, ERK1/2, and SYK.⁷⁻¹⁰ KIN-8194 blocked pBTK, pAKT, pERK1/2, and pSYK in a

dose-dependent manner in HCK^{WT}-expressing cells (Figure 3C). Conversely, attenuation of pAKT, pERK1/2, and pSYK was abrogated in HCK^{T333M}-expressing BCWM.1 and MWCL-1 cells. Importantly, pBTK continued to be inhibited by KIN-8194 in HCK^{T333M}-expressing BCWM.1 and MWCL-1 cells, which is consistent with our earlier binding studies showing BTK as an additional direct target of KIN-8194 (Figure 3C). Taken together, these data support that HCK and BTK are key targets of KIN-8194 activity in MYD88-mutated lymphoma cells, and their inhibition by KIN-8194 suppresses known downstream pro-survival signaling pathways.

KIN-8194 overcomes ibrutinib resistance related to BTK^{Cys481Ser}-expressing MYD88-mutated B-cell lymphoma cells

We next examined whether KIN-8194 could overcome ibrutinib resistance caused by the mutation of the nucleophilic cysteine residue BTK^{Cys481}. The expression of BTK^{Cys481Ser} resulted in a log1 fold-change to log2 fold-change in ibrutinib resistance in MYD88-mutated BCWM.1 and TMD-8 cells when compared with their BTK^{WT}- or vector only-expressing counterparts (Figure 4A). KIN-8194 overcame BTK^{Cys481Ser}-related resistance in these cells with similar antitumor activity observed in vector only-, BTK^{WT}-, and BTK^{Cys481Ser}-expressing BCWM.1 or TMD-8 cells (Figure 4A; supplemental Table 4). Moreover, KIN-8194 showed more robust induction of apoptosis relative to ibrutinib in BTK^{Cys481Ser}-expressing BCWM.1 and TMD-8 cells and at levels similar to those observed in BTK^{WT} cells (Figure 4B). KIN-8194 robustly blocked HCK as well as BTK and downstream ERK1/2 activation in vector-, BTK^{WT}-, and BTK^{Cys481Ser}-expressing BCWM.1 and TMD-8 cells (Figure 4C-D). These findings demonstrate that KIN-8194 blocks activation of HCK, BTK, and downstream ERK1/2 signaling in BTK^{Cys481}-mutated cells and overcomes ibrutinib resistance related to mutated BTK^{Cys481} expression in MYD88-mutated cells.

PK and tolerability of KIN-8194 in rodents

KIN-8194 is metabolized slowly after incubation with purified liver microsomes across multiple species: terminal half-life ($t_{1/2}$) for mice is 106.4 minutes, $t_{1/2}$ for rats is >120 minutes, $t_{1/2}$ for canines is 60 minutes, and $t_{1/2}$ for humans is 49.5 minutes. By comparison, microsomal stability was shorter for A419259 across species, including humans with a $t_{1/2}$ of 33.6 minutes (supplemental Figure 5). Cross-species studies showed comparable protein binding for KIN-8194: mice, 97.7%; rats, 95.5%; canines, 95.0%; and humans, 95.7%. By comparison, tighter protein binding was observed for A419259 across species, including 99.8% for humans (supplemental Figure 5). Consistent with the long microsomal stability of KIN-8194, mouse PK studies showed bioavailability of 55% and 49% after oral administration of 10 and 25 mg/kg, respectively (supplemental Figure 5). The serum half-life after intravenous administration was 11.5 hours, after oral administration of 10 mg/kg, it was 15.1 hours, and after oral administration of 25 mg/kg, it was 16.9 hours. By comparison, the serum half-life for A419259 was unpredictable and greatly prolonged at 176.0 hours (supplemental Figure 5).

KIN-8194 was well tolerated at oral doses up to 75 mg/kg once per day with no adverse events observed in NOD-SCID mice after 6 weeks of treatment. In vitro CYP inhibitions (percent at 10 μ M) for KIN-8194 were as follows: CYP1A, -27.9%; CYP2B6, +64.5%; CYP2CB, -3.8%; CYP2C9, -10.9%; CYP2C19, +0.8%; CYP2D6, +24.9%; CYP3A, -22.7% and -4.9%). Ames genotoxicity testing

was negative for 4 *Salmonella typhimurium* tester strains (TA98, TA100, TA1535, and TA1537) up to 50 μ M with and without metabolic activation by rat liver S9 fraction. hERG testing (patch clamp) for cardiotoxicity was negative at 16 μ M.

KIN-8194 shows superior activity over ibrutinib in MYD88-mutated TMD-8 ABC DLBCL xenograft mouse model

We performed PD studies using ibrutinib-sensitive BTK^{WT} TMD-8 ABC DLBCL cells xenografted into mice. Xenografted mice were administered KIN-8194 by oral gavage, and tumor cells were harvested at 6 and 24 hours after single administration of KIN-8194 at 12.5, 25, or 50 mg/kg. Fluorescence-activated cell sorting studies on excised tumors using phospho-specific antibodies demonstrated that KIN-8194 blocked pHCK and pBTK in a dose-dependent manner and maintained suppression for 24 hours for both HCK and BTK, particularly at higher dose levels (Figure 5A-B). Findings were similar after oral administration of KIN-8194 in mice xenografted with BTK^{WT} BCWM.1 WM cells by intravenous injection. Phosflow studies showed sustained reduction in both pHCK and pBTK in GFP⁺ BCWM.1 WM cells obtained from mouse femurs at 6 and 24 hours after oral administration of KIN-8194 at 25 or 50 mg/kg (supplemental Figure 6).

Given these findings, we next performed in vivo efficacy studies evaluating once-per-day oral administration of vehicle, ibrutinib (50 mg/kg), A419259 (50 mg/kg), and KIN-8194 (50 mg/kg) for 6 weeks (day 42), at which point treatment was stopped because 7 of 8 mice in the vehicle control cohort were moribund or had succumbed. Animals receiving KIN-8194 or ibrutinib showed good tolerance toward treatment during the 6-week treatment period, whereas labored breathing, ruffled fur indicative of lack of grooming, and toxicity were observed in mice receiving A419259. After 6 weeks, all surviving mice were observed off treatment for adverse events, tumor volume evolution, and survival. Significant volumetric differences in tumor size were observed among mice treated with vehicle control, ibrutinib, A419259, or KIN-8194 (Figure 5C-D). Mice that received vehicle control showed continued tumor growth, whereas those treated with ibrutinib, A419259, or KIN-8194 had significantly smaller tumors on day 33 (Figure 5D), which was near the median survival time for mice in the vehicle control group. After cessation of treatment at week 6, tumors in mice treated with ibrutinib and A419259 began to increase, whereas those in mice treated with KIN-8194 were undetectable or remained stable. By study end (day 113), 4 of 8 mice treated with KIN-8194 had no observable tumors, including by necropsy. For the other 4 mice, small palpable but not measurable subcutaneous tumors were detected. Consistent with these observations, mice treated with KIN-8194 showed superior survival with 6 of 8 mice alive at study end (Figure 5E). Conversely, the median survival was shorter at 31, 90, and 94.5 days for mice treated with vehicle control, ibrutinib, and A419259, respectively (Figure 5E).

KIN-8194 is active against ibrutinib resistance in BTK^{Cys481Ser}-expressing ABC DLBCL xenograft mouse model

We performed PD studies in mice engrafted with BTK^{Cys481Ser}-expressing TMD-8 cells. Xenografted mice received a single administration of KIN-8194 (25, 50, or 75 mg/kg) by oral gavage, and tumor cells were collected 6 and 24 hours later. KIN-8194




Figure 4. In vitro studies of KIN-8194 in ibrutinib-resistant BTK^{Cys481Ser}-expressing WM and ABC DLBCL cells. (A) Dose-response curves for vector only, BTK^{WT}, or BTK^{Cys481Ser} transduced BCWM.1 and TMD-8 cells after treatment with ibrutinib or KIN-8194 for 72 hours. (B) Apoptosis analyses with annexin V-fluorescein isothiocyanate (FITC) and PI staining for native, BTK^{WT}, and BTK^{Cys481Ser}-expressing BCWM.1 WM and TMD-8 ABC DLBCL cells after treatment with KIN-8194 or ibrutinib at the indicated concentrations for 16 hours. (C) Changes in pHCK^{Tyr410} expression after treatment with ibrutinib or KIN-8194 at indicated concentrations for 1.0 hours in vector only, BTK^{WT}, or BTK^{Cys481Ser} transduced BCWM.1 and TMD-8 cells. (D) Changes in pBTK^{Y223} and pERK1/2^{T202/Y204} levels after treatment with ibrutinib or KIN-8194 at indicated concentrations for 1.0 hours in vector only, BTK^{WT}, or BTK^{Cys481Ser} transduced BCWM.1 and TMD-8 cells. The expression levels of total BTK and ERK1/2 in these cells and protein loading control GAPDH are also shown. KIN, KIN-8194.




Figure 5. PD and efficacy studies of KIN-8194 in ibrutinib-sensitive BTK^{WT}-expressing TMD-8 ABC DLBCL xenografted mice. PD studies showing the activity of HCK and BTK after oral administration of KIN-8194 in NOD-SCID mice subcutaneously xenografted with ibrutinib-sensitive BTK^{WT} TMD-8 ABC DLBCL cells. Phosflow plots for (A) pHCK^{Y410} and (B) pBTK^{Y223} in GFP⁺ TMD-8 tumor cells excised at 6 and 24 hours after oral administration of KIN-8194 at the indicated doses ($n = 3$ per group). (C) Efficacy studies in NOD-SCID mice ($n = 8$ per cohort) bearing ibrutinib-sensitive BTK^{WT} TMD-8 cells after daily oral administration of vehicle control, ibrutinib, A419259, or KIN-8194 at 50 mg/kg. Tumor volume (mm^3) was measured twice per week and reported as the mean volume $\pm$ standard error of the mean (SEM). Treatment was stopped (indicated by green arrow) at day 42 and tumor volumes were monitored until day 113. (D) Tumor volume comparisons at day 33. P values for comparisons against mice treated with vehicle control are shown. (E) Survival curve estimations using the Kaplan-Meier method. The median survival (days) for cohorts were determined by using Prism software. $P < .0001$ for log-rank comparisons between cohorts. **** $P < .0001$.

effectively blocked pHCK and pBTK in a dose-dependent manner with inhibition of pHCK and pBTK maintained through 24 hours (Figure 6A-B). We next evaluated KIN-8194 activity in BTK^{Cys481Ser}-expressing TMD-8 xenografted mice. Xenografted mice were treated with vehicle, ibrutinib (50 mg/kg), A419259 (50 mg/kg), or KIN-8194 (50 mg/kg) by oral administration once per day. Treatment was stopped for all animals at day 49 because of labored breathing and ruffled fur in the A419259 cohort, and tumor volumes were monitored to day 59. Mice treated with KIN-8194 showed superior suppression of tumor growth and survival compared with mice receiving vehicle, ibrutinib, or A419259 (supplemental Figure 7). However, in contrast to our earlier findings, tumors in BTK^{WT} TMD-8 xenografted mice treated with KIN-8194 continued to show time-dependent progression.

Given these findings, we subsequently treated xenografted mice bearing BTK^{Cys481Ser}-expressing TMD-8 tumors with vehicle, ibrutinib (50 mg/kg), or KIN-8194 at 50 or 75 mg/kg once per day. Mice received treatment continuously for 16 weeks (day 113). Mice treated with KIN-8194 showed good tolerance to treatment and superior suppression of tumor growth, particularly at the highest dose (75 mg/kg), compared with animals treated with vehicle or ibrutinib (Figure 6C). Comparison of tumor volumes on day 29, near the median survival time for mice in the vehicle control group, showed significantly smaller tumor volumes for mice treated with KIN-8194 compared with mice treated with vehicle or ibrutinib (Figure 6D). Importantly, mice treated with KIN-8194 showed significantly longer survival, with a median survival of 57.5 days for those treated at 50 mg/kg and 70.5 days for those treated at 75 mg/kg. Conversely, median survival was 25 days for xenografted mice treated with vehicle and 29 days for xenografted mice treated with ibrutinib (Figure 6E).

KIN-8194 synergizes with the BCL_2 inhibitor venetoclax in MYD88-mutated B-cell lymphoma cells

Because inhibition of BCL_2 enhances ibrutinib apoptotic activity in MYD88-mutated WM and ABC DLBCL cells,^{25,26} we next examined whether the combination of KIN-8194 and venetoclax had a similar effect. By combination index and by normalized isobologram analyses, KIN-8194 showed synergistic interactions with venetoclax in both BTK^{WT}- and BTK^{Cys481Ser}-expressing BCWM.1 and TMD-8 cells at most dose combinations (Figure 7A). To evaluate the feasibility of using lower doses of KIN-8194 with venetoclax, mice xenografted with ibrutinib-resistant BTK^{Cys481Ser} TMD-8 cells were treated with this combination. A dose of 30 mg/kg per day representing ~50% effective dose for KIN-8194 (Figure 6C) and an intermediate effective dose of venetoclax (50 mg/kg per day) were used in these studies. Mice received treatment once per day with vehicle, KIN-8194, venetoclax, or KIN-8194 and venetoclax. Mice receiving KIN-8194 and venetoclax showed good tolerance to therapy as well as superior suppression of tumor growth compared with mice treated with vehicle, KIN-8194, or venetoclax alone (Figure 7). Tumor volume comparisons at the median survival time for mice in the vehicle control group (ie, day 22) showed significantly smaller tumors in xenografted mice that received KIN-8194 and venetoclax compared with those treated with vehicle, KIN-8194, or venetoclax alone (Figure 7C). Importantly, mice that received combination therapy showed significantly longer median survival (63 days) compared with mice that received vehicle control (22 days), venetoclax (27.5 days), or KIN-8194 (36 days) alone (Figure 7D).

Discussion

Given the importance of HCK and BTK in pro-survival signaling in MYD88-mutated lymphomas, we undertook an extensive medicinal chemistry effort to target these kinases. We describe KIN-8194, a pyrazolopyrimidine-based inhibitor that suppressed both HCK and BTK at sub-nanomolar levels with a high degree of selectivity. Target engagement studies confirmed both HCK and BTK binding at doses below pharmacologically achievable levels in rodents. KIN-8194 strongly abrogated HCK and BTK activity in MYD88-mutated cell lines as well as primary MYD88-mutated WM cells. KIN-8194 also abrogated downstream pro-survival signaling related to HCK and BTK, including AKT, ERK, and SYK. Although treatment of HCK^{WT} tumor cells with KIN-8194 abolished both pHCK and pBTK activities, treatment of HCK^{Thr333Met}-expressing cells that harbor a mutation at the gatekeeper ATP binding site resulted in loss of activity against HCK. Despite this, KIN-8194 still attenuated pBTK activity consistent with our molecular modeling and target engagement studies that showed direct binding of KIN-8194 to BTK. These studies support on-target activity of KIN-8194 against both HCK and its downstream mediator BTK.

KIN-8194 showed selective killing of MYD88-mutated lymphoma cells and primary WM cells which rely on both HCK and BTK for pro-survival signaling and had more potent anti-tumor activity compared with ibrutinib. Notably, neither ibrutinib nor KIN-8194 showed any activity in OCI-Ly-3 DLBCL cells that carry both mutated MYD88 and the CBM complex member CARD11. Mutations in CARD11 are downstream of BTK and are associated with ibrutinib resistance in ABC DLBCL patients, and therefore may be of consequence to the activity of KIN-8194 in certain ibrutinib-resistant patients.¹² In mice xenografted with ibrutinib-sensitive BTK^{WT} TMD-8 ABC DLBCL cells, KIN-8194 showed robust and sustained antitumor activity even after 6 weeks of treatment. Importantly, 4 (50%) of 8 mice showed no evidence of tumor during the 12 weeks of follow-up off treatment. Necropsies revealed no observable tumors in these animals suggestive of a curative potential for KIN-8194 after a limited duration of treatment. Compared with ibrutinib, KIN-8194 showed significantly longer survival at equivalent dosing in this ibrutinib-sensitive xenograft model.

Importantly, our *in vitro* studies also demonstrated that KIN-8194 abrogated both BTK and downstream ERK activation in ibrutinib-resistant BTK^{Cys481Ser}-expressing MYD88-mutated WM and ABC DLBCL cells. Our findings suggest that both BTK inhibition by blockade of upstream HCK activation and binding to non-Cys481 sites within BTK likely account for the activity of KIN-8194 in ibrutinib-resistant BTK^{Cys481Ser}-expressing tumor cells. Such a mechanistic approach may represent an advance in MYD88-mutated tumors over noncovalent inhibitors currently being developed for ibrutinib-resistant disease that target BTK alone,²⁷⁻²⁹ because the addition of HCK activity would block other pro-survival pathways such as ERK, AKT, and SYK in these tumors.^{8-10,19} Consistent with our *in vitro* findings, PD studies in mice engrafted with ibrutinib-resistant BTK^{Cys481}-mutated TMD-8 ABC DLBCL tumor cells showed that oral administration of KIN-8194 suppressed both BTK and HCK in a dose-dependent manner for 24 hours, which is consistent with a sustainable pharmacodynamic effect with daily dosing. At both 50 and 75 mg/kg per day continuous dosing, KIN-8194 produced superior suppression of tumor growth and a survival advantage in




Figure 6. PD and efficacy studies of KIN-8194 in ibrutinib-resistant BTK^{Cys481Ser}-expressing TMD-8 ABC DLBCL xenografted mice. PD studies showing the activity of HCK and BTK after oral administration of KIN-8194 in NOD-SCID mice subcutaneously xenografted with ibrutinib-resistant BTK^{Cys481Ser} TMD-8 ABC DLBCL cells. Phosflow plots for (A) p-HCK^{Y410} and (B) p-BTK^{Y223} in GFP⁺ TMD-8 tumor cells excised at 6 and 24 hours after oral administration of KIN-8194 at the indicated doses ($n = 3$ per group). (C) Efficacy studies in NOD-SCID mice ($n = 8$ per cohort) bearing ibrutinib-resistant BTK^{Cys481Ser} expressing TMD-8 cells after daily oral administration of vehicle control, ibrutinib (50 mg/kg), or KIN-8194 (50 or 75 mg/kg). Tumor volume (mm^3) was measured twice per week and reported as the mean volume $\pm$ SEM. (D) Tumor volume comparisons at day 29. P values are for cohort comparisons. (E) Survival curve estimations using the Kaplan-Meier method. Prism software was used to determine the median survival in days for cohorts. Mantel-Cox long-rank P value of .0007 is for comparisons between cohorts. * $P < .05$; ** $P < .01$; *** $P < .005$; **** $P < .0001$.




Figure 7. Studies assessing synergistic interactions of KIN-8194 and the BCL₂ inhibitor venetoclax. (A) In vitro studies assessed for synergistic interactions of KIN-8194 and venetoclax in native (untransduced), BTK^{WT}-, and BTK^{Cys481Ser}-expressing MYD88-mutated BCWM.1 WM and TMD-8 ABC DLBCL cells. The combination index (CI) and normalized isobologram analyses are depicted. CI < 1 (indicated in shades of red) or the dots under the oblique line in the isobologram plots indicate a synergistic effect for the combination. (B) Efficacy studies in NOD-SCID mice ($n = 8$ per cohort) bearing ibrutinib-resistant BTK^{Cys481Ser}-expressing TMD-8 cells after daily oral administration of vehicle control, venetoclax (50 mg/kg), KIN-8194 (30 mg/kg), or the combination of venetoclax (50 mg/kg) and KIN-8194 (30 mg/kg). Tumor volume (mm³) was measured twice per week and reported as the mean volume $\pm$ SEM. (D) Tumor volume comparisons at day 22. P values are for cohort comparisons. (E) Survival curve estimations using the Kaplan-Meier method. Prism software was used to determine the median survival in days for cohorts. $P = .002$ for log-rank comparisons between cohorts.

ibrutinib-resistant xenografts compared with mice treated with vehicle control or ibrutinib. The sustained antitumor effect and survival were longest in xenografted mice receiving KIN-8194 at 75 mg/kg per day.

Although KIN-8194 greatly prolonged survival in ibrutinib BTK^{Cys481}-mutated xenografts, the curative potential observed in BTK^{WT} xenografts was not recognized. Altered pro-survival signaling and inflammatory cytokine release introduced by mutated BTK^{Cys481} may underpin these findings.¹⁹ Indeed, comparison of PD data in BTK^{WT} and mutated BTK^{Cys481} obtained from excised tumors in mice treated with 50 mg/kg per day showed greater levels of HCK and BTK suppression in BTK^{WT} tumors. Given these findings, we sought to examine the potential synergistic benefit of BCL2 inhibition with KIN-8194. Our previous studies and those of others demonstrated the importance of BCL2 inhibition in enhancing ibrutinib activity.^{24,25} Herein, we observed that the addition of BCL2 inhibitor venetoclax to KIN-8194 led to synergistic interactions across most doses in both BTK^{WT} and BTK^{Cys481Ser}-expressing WM and ABC DLBCL cells driven by mutated MYD88. Consistent with the *in vitro* pharmacologic data, treatment of mice xenografted with ibrutinib-resistant BTK^{Cys481Ser}-expressing TMD-8 ABC DLBCL tumors with combined therapy showed superior inhibition of tumor growth and overall survival compared with xenografted mice receiving venetoclax or KIN-8194 alone.

Importantly, KIN-8194 showed distinct biological differences from A419259, a toolbox compound we previously characterized in MYD88 lymphomas, including ibrutinib-resistant BTK^{Cys481} mutant expressing cells.⁸ A419259 has a chemical structure that is similar to but different from that of KIN-8194. KIN-8194 demonstrated greater selectivity compared with A419259 with no KIT, RET, PDGFRA, EPHB6, or CDPK1 inhibition (at 90% kinase inhibition), an important consideration because several of these targets have well-known toxicity concerns. Moreover, more favorable human microsomal stability, human plasma protein binding, PK, efficacy, and tolerability in animal models, including xenografts with both WT and mutated BTK^{Cys481}-expressing tumors were observed with KIN-8194. The more favorable PK characteristics for KIN-8194 over A419259 may have contributed to the enhanced efficacy and tolerability because A419259 exhibited an unpredictable and prolonged serum half-life that could have resulted in drug accumulation.

In addition to MYD88-mutated WM and ABC DLBCL models evaluated herein, other B-cell malignancies driven by MYD88 such as PCNSL, MZL, and CLL may benefit from KIN-8194. Our preliminary rodent PK data showed that high drug concentrations of KIN-8194 in the central nervous system can be achieved, which provides a potentially targetable approach for treating PCNSL. More recently, the importance of HCK as a key driver for the growth and survival of mantle cell lymphoma has been reported.³⁰ Additional modeling studies are needed to examine the activity of KIN-8194 in these entities.

In summary, we described a novel dual inhibitor of HCK and BTK that showed potent and selective *in vitro* and *in vivo* activity against MYD88-mutated lymphomas, including ibrutinib-resistant BTK^{Cys481}-expressing tumors. These findings highlight the rational translation and targeting of HCK, a key driver of mutated MYD88

pro-survival signaling, and provide a framework for advancing KIN-8194 for B-cell malignancies driven by HCK and BTK.

Acknowledgments

The authors gratefully acknowledge Prafulla Gokhale and Michael J. Poitras at the Experimental Therapeutics Core, Dana-Farber Cancer Institute, for their excellent support for the animal studies and thank the WM patients who provided samples for these studies.

This work was supported by Peter Bing (the International Waldenström's Macroglobulinemia Foundation), by grants from the Leukemia and Lymphoma Society (R6507-18), the National Cancer Institute, National Institutes of Health, SPORC in Multiple Myeloma (2P50CA100707-16A1), Kinogen, the Edward and Linda Nelson Fund for Waldenström Macroglobulinemia (WM) Research, the Kerry Robertson Fund for WM Research, the Bauman Family Trust, and the Siegel Family Fund for WM.

Authorship

Contribution: G.Y., J.W., S.J.B., N.S.G., and S.P.T. conceived and designed the studies; G.Y. and S.P.T. wrote the manuscript; J.W., L.T., S.J.B., N.S.G., G.Y., and S.P.T. supported medicinal chemistry efforts; J.W. performed the data analysis; M.M. performed cellular *ex vivo* assays using patient biopsies and xenografted mouse tumors; X.L. maintained cell lines and performed lentiviral expression and knockdown studies; M.M. and A.K. performed signaling studies; G.Y. performed target engagement and synergy studies; G.Y. and J.G.C. performed compound screening; N.T., M.G.D., M.L.G., and L.X. processed patients' samples; Z.R.H. performed the statistical analysis; S.P.T., J.J.C., C.J.P., and K.M. provided patient care and collected patient samples; M.C. performed rodent tolerance studies and PK analyses; J.C. performed docking studies; and N.C.M. and K.C.A. provided data review and input into the writing of this manuscript.

Conflict-of-interest disclosure: S.P.T. received research funding, and/or consulting fees from AbbVie/Pharmaceuticals, Janssen Oncology, Beigene, Eli Lilly Pharmaceuticals, Bristol Myers Squibb, and Kinogen. N.S.G. is a founder, scientific advisory board member, and equity holder in Gatekeeper, Syros, Petra, C4, B2S, and Soltego (board member). G.Y., S.J.B., J.W., N.S.G., and S.P.T. are named inventors on a patent application covering KIN-8194 and targeting of HCK in MYD88-mutated diseases. K.C.A. received consulting fees from Bristol Myers Squibb, Celgene, Gilead, Janssen, Precision Biosciences, Sanofi-Aventis, Takeda, and Tolero and is on the board of directors of and stock options in Oncopep. N.C.M. is a consultant for Bristol Myers Squibb, Janssen, Oncopep, Amgen, Karyopharm, Legend, AbbVie, Takeda, and GlaxoSmithKline and is on the board of directors of and stock options in Oncopep. The Gray laboratory receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Her2ILc, Deerfield and Sanofi. The remaining authors declare no competing financial interests.

ORCID profiles: G.Y., 0000-0003-3049-4200; L.T., 0000-0002-1199-9046; J.G.C., 0000-0002-4565-832X; Z.R.H., 0000-0002-1689-1691; J.C., 0000-0003-4956-4811; J.J.C., 0000-0001-9490-7532; M.C., 0000-0003-3154-4775; N.S.G., 0000-0001-5354-7403; S.P.T., 0000-0001-6393-6154.

Correspondence: Steven P. Treon, Dana-Farber Cancer Institute, M548, 450 Brookline Ave, Boston, MA 02115; e-mail: steven_treon@dfci.harvard.edu.

Footnotes

Submitted February 26, 2021; accepted May 27, 2021; prepublished online on Blood First Edition June 16, 2021. DOI 10.1182/blood.2021011405.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

REFERENCES

1. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. *N Engl J Med*. 2012; 367(9):826-833.
2. Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. *Blood*. 2013;121(11):2051-2058.
3. Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. *Neuropathol Appl Neurobiol*. 2016;42(3):279-290.
4. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. *Nature*. 2011;470(7332):115-119.
5. Martinez-Lopez A, Curiel-Olmo S, Mollejo M, et al. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma. *Am J Surg Pathol*. 2015;39(5):644-651.
6. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. *Cell*. 2013; 152(4):714-726.
7. Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. *Blood*. 2013;122(7):1222-1232.
8. Yang G, Buhrlage SJ, Tan L, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. *Blood*. 2016;127(25):3237-3252.
9. Liu X, Chen JG, Munshi M, et al. Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. *Blood Adv*. 2020;4(1):141-153.
10. Munshi M, Liu X, Chen JG, et al. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. *Blood Cancer J*. 2020;10(1):12.
11. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. *N Engl J Med*. 2015; 372(15):1430-1440.
12. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. *Nat Med*. 2015;21(8):922-926.
13. Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. *Cancer Discov*. 2017;7(9):1018-1029.
14. Chen R, de Vos S, Thieblemont C, et al. Ibrutinib therapy in patients with relapsed/refractory marginal zone lymphoma: Analysis by prior rituximab treatment and baseline mutations [abstract]. *Blood*. 2017;130(suppl 1). Abstract 3026.
15. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *N Engl J Med*. 2014;370(24):2286-2294.
16. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. *Blood*. 2017; 129(11):1469-1479.
17. Xu L, Tsakmaklis N, Yang G, et al. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. *Blood*. 2017;129(18):2519-2525.
18. Epperla N, Shana'ah AY, Jones D, et al. Resistance mechanism for ibrutinib in marginal zone lymphoma. *Blood Adv*. 2019;3(4):500-502.
19. Chen JG, Liu X, Munshi M, et al. BTK^{Cys481Ser} drives ibrutinib resistance via ERK1/2 and protects BTK^{wild-type} MYD88-mutated cells by a paracrine mechanism. *Blood*. 2018;131(18):2047-2059.
20. Yang G, Wang J, Tan L, et al. A novel HCK inhibitor Kin-8193 blocks BTK activity in BTK^{Cys481} mutated ibrutinib resistant B-cell lymphomas driven by mutated MYD88 [abstract]. *Blood*. 2018;132(suppl 1). Abstract 40.
21. Burchat AF, Calderwood DJ, Friedman MM, et al. Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck – a selectivity insight. *Bioorg Med Chem Lett*. 2002;12(12):1687-1690.
22. Saito Y, Yuki H, Kuratani M, et al. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. *Sci Transl Med*. 2013; 5(181):181ra52.
23. Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. *Nat Biotechnol*. 2011;29(11):1046-1051.
24. Patricelli MP, Szardenings AK, Liyanage M, et al. Functional interrogation of the kinome using nucleotide acyl phosphates. *Biochemistry*. 2007;46(2):350-358.
25. Cao Y, Yang G, Hunter ZR, et al. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 wild-type and CXCR4 WHIM mutated Waldenström macroglobulinemia cells. *Br J Haematol*. 2015;170(1):134-138.
26. Kuo HP, Ezell SA, Schweighofer KJ, et al. Combination of ibrutinib and ABT-199 in diffuse large B-cell lymphoma and follicular lymphoma. *Mol Cancer Ther*. 2017;16(7):1246-1256.
27. Allan JN, Patel K, Mato AR, et al. Ongoing results of a phase 1B/2 dose-escalation and cohort-expansion study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor, vecabrutinib, in B-cell malignancies [abstract]. *Blood*. 2019;134(suppl 1). Abstract 3041.
28. Gomez EB, Isabel L, Rosendahl MS, et al. Loxo-305, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations [abstract]. *Blood*. 2019;134(suppl 1). Abstract 4644.
29. Woyach J, Stephens DM, Flinn IW, et al. Final results of Phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies [abstract]. *Blood*. 2019;134(suppl 1). Abstract 4298.
30. Lantermans HC, Minderman M, Kuil A, et al. Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma. *Leukemia*. 2021;35:881-886.